TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TScan Therapeutics reported second quarter 2026 financial results and corporate updates highlighting the dosing of the first patient in the Phase 3 ALLOHA-2 study evaluating their lead TCR-T therapy candidate TSC-101. Positive initial data from the Phase 1 ALLOHA study validated their commercial-ready manufacturing process. The company has a health…